Relief Therapeutics Holding (OTCMKTS:RLFTF) is making a strong comeback after yesterday’s profit taking. The stock has seen selling pressure so far this year with a fall of 29% YTD.
As of 7:53, RLFTF stock jumped $0.01 or 4.76% to $0.22 on moderate volume of 636K shares. The stock has moved within a range of $0.2192 – 0.2256 after opening the trade at $0.2256.
Relief Appoints Dr. Taneli Jouhikainen as Chief Operating Officer
- today announced the appointment of Taneli Jouhikainen, M.D., MBA, to the newly created position of Chief Operating Officer (COO), effective June 1, 2021. The position was created to stay abreast with Relief’s strategic transition from a clinical-stage company to a diversified, fully integrated product-driven entity.
- Dr. Jouhikainen will oversee all internal product development and intellectual property activities and will be an important contributor to the Company’s growth strategy and corporate development efforts. He will also be responsible for the overall integration of new activities and programs into Relief.
- Dr. Taneli Jouhikainen has over 25 years of life sciences expertise. He joins Relief from Savara, a Nasdaq-listed clinical stage biopharmaceutical company focused on rare respiratory diseases, where he was Co-Founder and President & COO. Prior to this, he served at Akela Pharma Inc., a public clinical stage specialty pharmaceutical company focused on orphan drugs and inhalation products, first as Head of Corporate Development and subsequently as CEO until the company’s merger with Nventa Biopharmaceuticals.
- He served in senior executive roles at various other life sciences companies, including LAB International, Inc. and Focus Inhalation Oy, and was Head of Clinical Development at Leiras, a subsidiary of Schering AG. Dr. Jouhikainen holds an M.D. and a Ph.D. in hematology and immunology from the University of Helsinki and an MBA from the Helsinki School of Economics.